Enzolytics, Inc. announced on September 18 that it sold two of its wholly owned subsidiaries, Biogenysis, Inc. and Virogentics, Inc., to Sagaliam Acquisition Corp. in a transaction valued at $450 million.
Enzolytics is a Texas-based biotechnology company with both patented anti-HIV therapeutics and a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy.
Biogenysis uses proprietary techniques to produce fully human monoclonal antibodies (mAbs) against infectious diseases. The technology is currently being employed to produce monoclonal antibody therapeutics for treating the CoronaVirus (SARS-CoV-2), HIV-1 and the Feline Leukemia Virus.
Virogentics is a biotechnology company that makes IPF Immune™, a liquid nutritional supplement that acts as an immune modulator to benefit the immune system by fortifying it against infections.
Sagaliam Acquisition Corp. is a special purpose acquisition company based in Los Angeles, California.
According to data captured in the LevinPro HC database, this acquisition represents the 109th Biotechnology acquisition of 2023. This transaction was aimed to bring more funding to Sagaliam’s platform to further develop its pipeline.
